drugset / Trial / NCT01608724

The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus

NCT01608724

Phase 4 Completed 2165 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.

Timeline

Start
2012-11
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral